- Home
- SA vs MLYS Comparison
SA vs MLYS Comparison
Compare SA & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SA
- MLYS
- Stock Information
- Founded
- SA 1979
- MLYS 2019
- Country
- SA Canada
- MLYS United States
- Employees
- SA N/A
- MLYS N/A
- Industry
- SA Precious Metals
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- SA Basic Materials
- MLYS Health Care
- Exchange
- SA Nasdaq
- MLYS Nasdaq
- Market Cap
- SA 1.0B
- MLYS 893.0M
- IPO Year
- SA N/A
- MLYS 2023
- Fundamental
- Price
- SA $11.43
- MLYS $13.84
- Analyst Decision
- SA
- MLYS Strong Buy
- Analyst Count
- SA 0
- MLYS 3
- Target Price
- SA N/A
- MLYS $27.00
- AVG Volume (30 Days)
- SA 667.2K
- MLYS 2.2M
- Earning Date
- SA 05-12-2025
- MLYS 05-08-2025
- Dividend Yield
- SA N/A
- MLYS N/A
- EPS Growth
- SA N/A
- MLYS N/A
- EPS
- SA N/A
- MLYS N/A
- Revenue
- SA N/A
- MLYS N/A
- Revenue This Year
- SA N/A
- MLYS N/A
- Revenue Next Year
- SA N/A
- MLYS N/A
- P/E Ratio
- SA N/A
- MLYS N/A
- Revenue Growth
- SA N/A
- MLYS N/A
- 52 Week Low
- SA $10.14
- MLYS $8.24
- 52 Week High
- SA $20.55
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- SA 46.35
- MLYS 50.18
- Support Level
- SA $11.27
- MLYS $16.15
- Resistance Level
- SA $12.54
- MLYS $17.21
- Average True Range (ATR)
- SA 0.49
- MLYS 1.44
- MACD
- SA 0.01
- MLYS -0.21
- Stochastic Oscillator
- SA 12.60
- MLYS 19.07
About SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.